. Cilostazol [6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2-(1H)-quinolinone] is a phosphodiesterase of the Type (PDE3) inhibitor and increases intracellular cyclic AMP (cAMP) levels via restraining hydrolysis of PDE3. The main actions of this compound are vasodilatation with restraint of platelet aggregation 4, 5) and a potential protective effect against atherosclerosis 6) .
In vascular endothelial cells, the elevation of cAMP level leads to protein kinase A (PKA) activation followed by NO production 7, 8) , which may explain the anti-adhesive effect of cilostazol in endothelial cells 5) .
On the other hand, its effect on monocytes remains unclear. To gain more information about the cilostazol
Introduction
Atherosclerosis is a complex disease process associated with vascular wall dysfunction. The adhesion of circulating monocytes to the intimal endothelial cell monolayer is thought to be one of the earliest events in naturally occurring human and experimental animal models of atherosclerosis 1) . Numerous adhesion receptors and counter receptors expressed on both endothelial cells and leukocytes appear to be involved in effect on atherosclerosis, we demonstrated the effects of cilostazol in monocytes and their adhesion to vascular endothelial cells.
Materials and Methods

Reagents
RPM1640, fetal bovine serum (FBS), and forskolin were purchased from Sigma (Japan). Endothelial cell growth factor and recombinant human TNFwere obtained from R&D Systems (Minneapolis, MN). Cilostazol was a gift from Otsuka Pharmaceutical (Japan). Dibutyryl-cAMP was purchased from Wako (Japan). HUTS21 was purchased from BD Biosciences Pharmingen (San Jose, CA). VLA4 was purchased from Upstate (Lake Placid, NY). CD18 was purchased from Southern Biotechnology Associates (Birmingham, AL). 7A10 was a gift from the Scripps Research Institute (La Jolla, CA).
Cell Culture
THP-1 cells were obtained from the American Type Culture Collection and grown in RPMI1640 medium containing 10% FBS, 100 U/mL of penicillin, 100 g/mL of streptomycin, and 2 mM L-glutamine. Human umbilical vein endothelial cells (HUVECs) were isolated from normal term-umbilical veins and established in culture as previously described 9) . Primary cultures were serially passaged ( 1:3 split ratio) and maintained in medium 199 buffered with 25 mmol/L of RPMI1640 and supplemented with 20% FBS, endothelial cell growth factor (10 g/mL), 100 U/mL of penicillin, 100 g/mL of streptomycin, and porcine intestinal heparin (50 g/mL). For the experiments, HUVECs were sub-cultured to passage 2 or 3 and used.
Viability Test
To test THP-1 cell viability, we performed 6-diamidino-2-phenylindole (DAPI) (purchased from Dojindo, Japan) staining. THP-1 cells were treated with cilostazol for 48 hours at the concentrations indicated in Table 1 . DAPI staining was observed under a fluorescence microscope and the number of DAPI-positive cells was counted.
Adhesion Assay under Laminar Flow
The parallel-plate flow chamber used in the present study has been previously described in detail 10, 11) . Briefly, the chamber was composed of 2 aluminum steel plates separated by a 200-m-thick silastic gasket, with a flow channel formed by removal of a 5 20-mm rectangular section of the gasket. Defined levels of flow were applied to the HUVEC monolayer by drawing the perfusion medium (D-PBS containing 0.2% human serum albumin) through the channel with a syringe pump (model 44 Harvard Apparatus). A plastic heating plate (Tokai Hit Co) was mounted on the stage of an inverted microscope ( 50, Olympus) to maintain the temperature at 37 . Endothelial monolayers on the coverslips were stimulated with TNF-for 4 hours and then positioned in the flow chamber, which was mounted on an inverted microscope. The monolayers were perfused for 5 minutes with perfusion medium and then examined carefully to verify them as confluent. Next, THP-1 cells were added to the perfusion medium to 10 6 cells/mL, and then drawn through the chamber for 10 minutes at controlled flow rates to generate calculated wall shear stresses of 1.0 and 2.0 dyne/cm 2 . The entire period of perfusion was recorded on videotape with a digital video recorder that included a time generator. Captured images were then transferred to a PC for image analysis to determine the number of rolling and adherent cells in 5 to 10 randomly selected 20-times magnified microscopic fields for each experiment. Cells were considered to be adherent after 10 seconds of stable contact with the monolayer. Rolling leukocytes were easily recognized, because their velocity was much slower (up to 80 m/s) than that of free-flowing cells. We then measured the rolling velocity using analysis software.
Flow Cytometry
THP-1 cells were first incubated with the indicated primary antibodies on ice for 40 minutes, washed twice with RPMI-1640 medium containing 5% FBS, and then incubated with fluorescein isothiocyanate (FITC) labeled goat anti-mouse antibody (1:250 dilution). Fluorescence intensity was analyzed with a fluorescence-activated cell sorting system (FACSCaliber, Becton-Dickinson).
cAMP Enzyme Immunoassay
THP-1 cells were incubated in the presence of 
Expression Levels of Integrin after Cilostazol Treatment
Expression levels of integrin in THP-1 cells were cilostazol at 5 M for 48 hours, and cAMP concentration in THP-1 cells was measured using a cAMP EIA Kit [Cayman Chemical Company: Ann Arbor, MI], following the manufacture's protocol. In brief, THP-1 associated cAMP (2 10 6 /count) was extracted using 0.1 M HCl. AChE tracer and cAMP EIA antiserum were added to 200 mL of extracted sample. cAMP activity was measured using a plate reader.
Statistical Analysis
Data are presented as the mean SEM as indicated. Statistical significance was calculated by one-way ANOVA with Tukey's post-hoc analysis. P-values 0.05 were considered significant.
Results
Measurement of Viability
First, we examined THP-1 cell viability by DAPI staining after cilostazol treatment. As shown in Table  1 , cilostazol did not influence THP-1 cell viability at any concentration.
Effect of Cilostazol on Adhesion of THP-1 Cells to Vascular Endothelium
We examined the adhesion of THP-1 cells preincubated in the presence or absence of the indicated amount of cilostazol to activated vascular endothelium. As shown in On the other hand, the number of rolling THP-1 cells was not significantly changed. Interestingly, incubation with cilostazol at 10 M failed to reduce THP-1 cell adhesion. Next, we examined the time kinetics of the anti-adhesive effect of cilostazol at 5 M. As shown in Fig. 1B , incubation with cilostazol gradually reduced THP-1 cell adhesion to activated HUVECs in a time-dependent manner. Representative microphotos of these interactions are shown in Fig. 2 . Since preincubation with ciloztazol for 48 hrs significantly inhibited THP-1 adhesion, we incubated THP-1 cells with cilostazol at 5 M for 48 hrs.
Effect of Cilostazol in Rolling Velocity of THP-1 Cells
We next examined the potential effect of cilostazol on the rolling velocity of THP-1 cells over activated HUVECs. As shown in Fig. 3 , the rolling velocity measured after cilostazol treatment and compared with control THP-1 cells. As far as we tested using antibodies against integrin-1, VLA4, and integrin-2, we did not detect any significant change by flow cytometry (data not shown).
cAMP Concentration is Increased in THP-1 Cells after Cilostazol Treatment
To further dissect the molecular mechanism of cilostazol-dependent modulation of THP-1 adhesion, we measured the cAMP concentration of THP-1 cells, which correlated with the amount of PDE inhibition by cilostazol. As shown in Fig. 4A , the concentration of cAMP was significantly increased after cilostazol treatment.
High-Concentration cAMP in THP-1 Cells by other Reagents Leads to Diminished Adhesion to Activated HUVEC
To evaluate the importance of cAMP concentration in cell adhesive intereaction, we incubated THP-1 cells with forskolin and dibutyryl-cAMP, known inducers of cAMP. Treatment with forskolin and dibutyryl-cAMP inhibited THP-1 cell adhesion to activated HUVECs comparable to cilostazol (Fig. 4B) .
Discussion
Leukocyte-endothelial interactions contribute to a variety of vascular disease processes, such as acute and chronic inflammation, and atherosclerosis 5, 6, 12) . A number of soluble factors and cell surface adhesion in monocytic THP-1 cells confirmed the anti-inflammatory properties of cilostazol.
In conclusion, we have demonstrated that cilostazol inhibited monocytic THP-1 cell adhesion to activated endothelial cells via the elevation of cAMP in THP-1 cells. Our data may point to a new therapeutic potential of this compound. molecules, expressed by both endothelial cells and leukocytes, interact in a complex fashion to efficiently mediate leukocyte recruitment 13) . Cyclic nucleotide phosphodiesterase 3 (PDE3) belongs to the PDE family 14, 15) , and is important in cyclic AMP (cAMP) -mediated signaling in vascular smooth muscle cells 15) . Intracellular cAMP level is regulated by their synthesis by adenylyl cyclases and hydrolysis by PDEs 16) . Cilostazol is a PDE3 inhibitor, and has been shown to affect endothelial cells to inhibit leukocyte and platelet adhesion 2, 17, 18) ; however, the effect of cilostazol on monocytes was not extensively studied. Here we showed for the first time that cilostazol affects monocytes and reduces its adhesion to vascular endothelial cells under physiological flow conditions.
As shown in Fig. 1 , inhibition of cell adhesion by cilostazol was prominent up to 5 M, but diminished at 10 M. We speculated that a high concentration of cilostazol (10 M) lost its anti-adhesive effect by cell damage, the activation of various factors, or other factors, although this was not detected by DAPI staining (Table 1) . When THP-1 cells were treated at 5 M, we also observed the reduction of rolling velocity (Fig. 3) . We thought that cilostazol inhibited not only stable adhesion but also the transition from rolling to stable adhesion that could be reflected in the change in rolling velocity. We would like to focus on the effect of cilostazol on rolling interaction in future projects.
In this study, we were able to demonstrate elevation of cAMP by cilostazol in monocytic cells. cAMP has been shown as a gating element in a number of different signaling pathways in monocytes 19) and it has been reported that elevation of cAMP in lymphocytes led to the suppression of immune functions by a protein kinase A-dependent mechanism 20) . Platelet aggregation was suppressed 21) by activation of PKA accompanying the rise of cAMP. cAMP enhanced NO production from endothelial cells 7, 8) by PKA and induced vasodilation. In addition, cAMP reduced intracellular Ca 2 concentration 22) and production of thromboxane A2 (TXA2) in platelets, thus leading to the inhibition of platelet aggregation 23) . Although we did not have direct evidence to link cAMP elevation and adhesive interaction in THP-1 cells, future studies will reveal this mechanism in detail.
It has been reported that cilostazol controlled VCAM-1 expression via inhibiting the activation of nuclear factor-kappaB 24) . In another report, it inhibited the expression of interleukin 1 (IL-1) beta, myeloperoxidase (MPO), and cytokine-induced neutrophil chemoattractant-1 (GRO/CINC-1) 25) in neutrophils. In line with these previous observations, our findings
